Caroline Robert, MD, PhD, on Immunotherapy Toxicities: Expert Perspective
ESMO 2018 CongressCaroline Robert, MD, PhD, of Gustave Roussy Cancer Centre, discusses managing toxicities of immunotherapy, including neurotoxicity, and treating beyond acute adverse events.
Related Videos
Johan F. Vansteenkiste, MD, PhD, on NSCLC: Immunotherapy and Targeted Treatments
Johan F. Vansteenkiste, MD, PhD, of Catholic University Leuven, summarizes a session he co-chaired that included discussion of translating advances in stage IV disease to nonmetast...
Lisa A. Carey, MD, and Sherene Loi, MD, PhD, on TNBC: Combination Immune Checkpoint Inhibitor Therapy
Lisa A. Carey, MD, of the University of North Carolina, and Sherene Loi, MD, PhD, of the Peter MacCallum Cancer Centre, discuss the phase III IMpassion 130 trial t...
Martin Reck, MD, PhD, on Immunotherapy for Thoracic Malignancies: Expert Perspective
Martin Reck, MD, PhD, of the LungenClinic, discusses recent updates on biomarkers beyond PD-L1 expression; mechanisms and management of resistance; as well as combinations an...
Laurence Albiges, MD, PhD, on RCC: Challenging Established Front-Line Treatment
Laurence Albiges, MD, PhD, of Gustave Roussy, discusses data from the global, phase III JAVELIN trial that compared axitinib plus avelumab vs sunitinib, which could lead to a new s...
Caroline Robert, MD, PhD, on Advanced Melanoma: Research Highlights
Caroline Robert, MD, PhD, of Gustave Roussy Cancer Centre, discusses two high-impact studies in stage III melanoma treatment: an update of the COMBI-AD trial examining dabrafenib a...
